Faculty of Medicine, Department of Immunology-Allergology-Rheumatology, University of Antwerp, Universiteitsplein 1, Antwerp, Belgium.
Pediatr Allergy Immunol. 2011 Feb;22(1 Pt 2):e139-49. doi: 10.1111/j.1399-3038.2011.01112.x.
Symptoms of hazelnut allergy seem related to geographic and possibly age variations in allergen recognition.
To investigate sensitization profiles of hazelnut allergy in different age groups in a birch-endemic region using component resolved diagnosis (CRD) by microarray.
Sixty-five patients with hazelnut allergy, 27 healthy control individuals tolerant to hazelnut, and 34 birch pollen allergic but hazelnut tolerant individuals were included. All blood samples were analyzed using ISAC microarray.
Twenty-nine patients with hazelnut allergy suffered from a systemic reaction (17 preschool children with a median age of 2 years, six school children, and six adults), whereas 36 patients reported an oral allergy syndrome (OAS; three preschool and nine school children and 24 adults). In the hazelnut allergic preschool children with systemic reactions, 65% were sensitized to Cor a 9, 12% to Cor a 8, 18% to Cor a 1.04, 6% to Cor a 1.0101, and 29% to Bet v 1. Of the school-aged systemic reactors, 50% were sensitized to Cor a 9, 17% to Cor a 8, 50% to Cor a 1.04 and Cor a 1.0101, and 67% to Bet v 1. In adults with hazelnut allergy, 3.3% were sensitized to Cor a 9, 6.7% to Cor a 8, 90% to Cor a 1.04 and Bet v 1, and 87% to Cor a 1.0101. In regard to systemic reactors in this group, 17% were sensitized to Cor a 9, 33% to Cor a 8 and Cor a 1.0101, and 50% to Cor a 1.04 and Bet v 1. In the patients with OAS, irrespective the age group, all were sensitized to Bet v 1 and over 97% to Cor a 1.04 and Cor a 1.0101. No sensitization to Cor a 9 or Cor a 8 was found in patients with only an OAS. Of the patients with birch pollen allergy, tolerant to hazelnut, none were sensitized to Cor a 9 or Cor a 8, 56% to Cor a 1.0101, 82% to Cor a 1.04, and 92% to Bet v 1. In healthy controls, no sensitization to components of hazelnut, hazel pollen or birch pollen was demonstrable.
Hazelnut allergy in a birch-endemic region exhibits age-related sensitization profiles with distinct clinical outcomes that can be identified using CRD. The majority of hazelnut allergic preschool and school children in a birch-endemic region show systemic reactions on consumption of processed hazelnut, mostly being sensitized to the hazelnut legumin-like allergen Cor a 9 but unrelated to birch pollen allergy. In contrast, adults generally suffer from an OAS apparently as a result of cross-reactivity between Cor a 1.04 from hazelnut and Bet v 1 from birch pollen.
榛子过敏的症状似乎与过敏原识别的地域和年龄变化有关。
使用微阵列的成分分辨诊断(CRD)研究桦木流行地区不同年龄组榛子过敏的致敏谱。
纳入 65 例榛子过敏患者、27 例对榛子耐受的健康对照者和 34 例桦树花粉过敏但对榛子耐受的个体。所有血液样本均采用 ISAC 微阵列进行分析。
29 例榛子过敏患者发生全身性反应(17 例学龄前儿童,中位年龄 2 岁,6 例学龄儿童和 6 例成人),36 例患者报告口腔过敏综合征(OAS;3 例学龄前儿童和 9 例学龄儿童和 24 例成人)。在有全身性反应的榛子过敏学龄前儿童中,65%对 Cor a 9 致敏,12%对 Cor a 8 致敏,18%对 Cor a 1.04 致敏,6%对 Cor a 1.0101 致敏,29%对 Bet v 1 致敏。学龄期全身性反应者中,50%对 Cor a 9 致敏,17%对 Cor a 8 致敏,50%对 Cor a 1.04 和 Cor a 1.0101 致敏,67%对 Bet v 1 致敏。在成人榛子过敏患者中,3.3%对 Cor a 9 致敏,6.7%对 Cor a 8 致敏,90%对 Cor a 1.04 和 Bet v 1 致敏,87%对 Cor a 1.0101 致敏。对于该组的全身性反应者,17%对 Cor a 9 致敏,33%对 Cor a 8 和 Cor a 1.0101 致敏,50%对 Cor a 1.04 和 Bet v 1 致敏。在 OAS 患者中,无论年龄组如何,所有患者均对 Bet v 1 致敏,超过 97%对 Cor a 1.04 和 Cor a 1.0101 致敏。仅发生 OAS 的患者中未发现对 Cor a 9 或 Cor a 8 的致敏。在桦树花粉过敏但对榛子耐受的患者中,无一例对 Cor a 9 或 Cor a 8 致敏,56%对 Cor a 1.0101 致敏,82%对 Cor a 1.04 致敏,92%对 Bet v 1 致敏。健康对照者中,未发现榛子、榛花粉或桦树花粉成分的致敏。
桦木流行地区的榛子过敏表现出与年龄相关的致敏谱,具有不同的临床结果,可通过 CRD 识别。桦木流行地区的大多数学龄前和学龄期榛子过敏儿童在食用加工榛子时会出现全身性反应,主要对榛子球蛋白样过敏原 Cor a 9 致敏,但与桦树花粉过敏无关。相比之下,成人通常患有 OAS,这显然是由于榛子中的 Cor a 1.04 与桦树花粉中的 Bet v 1 之间的交叉反应引起的。